Click here to get full coverage on Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR - MarketBeat

Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR  MarketBeat

Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR - MarketBeat

Click here to get full coverage on Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga

Xencor Faces Structural Headwinds As Long-Term Momentum Fades  Benzinga

Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga

Click here to get full coverage on Barclays Raises XNCR Price Target to $26; Reaffirms Overweight R - GuruFocus

Barclays Raises XNCR Price Target to $26; Reaffirms Overweight R  GuruFocus

Barclays Raises XNCR Price Target to $26; Reaffirms Overweight R - GuruFocus

Click here to get full coverage on Will XNCR stock attract more institutional investors - July 2025 Update & Free Risk Controlled Daily Trade Plans - Улправда

Will XNCR stock attract more institutional investors - July 2025 Update & Free Risk Controlled Daily Trade Plans  Улправда

Will XNCR stock attract more institutional investors - July 2025 Update & Free Risk Controlled Daily Trade Plans - Улправда

Click here to get full coverage on Xencor (XNCR): Evaluating Valuation Following Early XmAb819 Trial Results Announcement - Yahoo Finance

Xencor (XNCR): Evaluating Valuation Following Early XmAb819 Trial Results Announcement  Yahoo Finance

Xencor (XNCR): Evaluating Valuation Following Early XmAb819 Trial Results Announcement - Yahoo Finance

Click here to get full coverage on Assessing Xencor (XNCR) Valuation After New U.S. Patent Extends Ultomiris Royalty Stream - simplywall.st

Assessing Xencor (XNCR) Valuation After New U.S. Patent Extends Ultomiris Royalty Stream  simplywall.st

Assessing Xencor (XNCR) Valuation After New U.S. Patent Extends Ultomiris Royalty Stream - simplywall.st

Click here to get full coverage on Xencor Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Xencor Stock Jump Looks Great, But How Secure Is That Gain?  Trefis

Xencor Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Acadia Healthcare (ACHC) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Acadia Healthcare (ACHC)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Acadia Healthcare (ACHC) - The Globe and Mail

Click here to get full coverage on Barclays Upgrades Xencor (XNCR) - Nasdaq

Barclays Upgrades Xencor (XNCR)  Nasdaq

Barclays Upgrades Xencor (XNCR) - Nasdaq

Click here to get full coverage on Truist Financial Maintains Xencor(XNCR.US) With Buy Rating - 富途牛牛

Truist Financial Maintains Xencor(XNCR.US) With Buy Rating  富途牛牛

Truist Financial Maintains Xencor(XNCR.US) With Buy Rating - 富途牛牛

Click here to get full coverage on Xencor slides amid plans for early-stage trial data for kidney cancer drug - Seeking Alpha

Xencor slides amid plans for early-stage trial data for kidney cancer drug  Seeking Alpha

Xencor slides amid plans for early-stage trial data for kidney cancer drug - Seeking Alpha

Click here to get full coverage on New Analyst Forecast: $XNCR Given $18.0 Price Target - Quiver Quantitative

New Analyst Forecast: $XNCR Given $18.0 Price Target  Quiver Quantitative

New Analyst Forecast: $XNCR Given $18.0 Price Target - Quiver Quantitative

Click here to get full coverage on Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? - Yahoo Finance

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?  Yahoo Finance

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? - Yahoo Finance

Click here to get full coverage on $XNCR stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

$XNCR stock is up 10% today. Here's what we see in our data.  Quiver Quantitative

$XNCR stock is up 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on $XNCR stock is up 13% today. Here's what we see in our data. - Nasdaq

$XNCR stock is up 13% today. Here's what we see in our data.  Nasdaq

$XNCR stock is up 13% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Does Xencor’s Sharply Reduced Loss in Q3 2025 Signal a Turnaround for XNCR? - simplywall.st

Does Xencor’s Sharply Reduced Loss in Q3 2025 Signal a Turnaround for XNCR?  simplywall.st

Does Xencor’s Sharply Reduced Loss in Q3 2025 Signal a Turnaround for XNCR? - simplywall.st

Click here to get full coverage on Xencor, Inc. $XNCR Shares Acquired by Panagora Asset Management Inc. - MarketBeat

Xencor, Inc. $XNCR Shares Acquired by Panagora Asset Management Inc.  MarketBeat

Xencor, Inc. $XNCR Shares Acquired by Panagora Asset Management Inc. - MarketBeat

Click here to get full coverage on Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent Extension - What's Changed - simplywall.st

Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent Extension - What's Changed  simplywall.st

Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent Extension - What's Changed - simplywall.st

Click here to get full coverage on Xencor price target raised to $26 from $23 at Barclays - TipRanks

Xencor price target raised to $26 from $23 at Barclays  TipRanks

Xencor price target raised to $26 from $23 at Barclays - TipRanks

Click here to get full coverage on Clinical-Stage Biotech Xencor Announces Back-to-Back Presentations at Major Healthcare Conferences - Stock Titan

Clinical-Stage Biotech Xencor Announces Back-to-Back Presentations at Major Healthcare Conferences  Stock Titan

Clinical-Stage Biotech Xencor Announces Back-to-Back Presentations at Major Healthcare Conferences - Stock Titan

Click here to get full coverage on RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating - Finviz

RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating  Finviz

RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating - Finviz

Click here to get full coverage on Xencor, Inc.: No Major Near Term Catalysts (NASDAQ:XNCR) - Seeking Alpha

Xencor, Inc.: No Major Near Term Catalysts (NASDAQ:XNCR)  Seeking Alpha

Xencor, Inc.: No Major Near Term Catalysts (NASDAQ:XNCR) - Seeking Alpha

Click here to get full coverage on Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR - MarketBeat

Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR  MarketBeat

Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR - MarketBeat

Click here to get full coverage on Xencor stock maintains Overweight rating at Cantor Fitzgerald ahead of key webcast - Investing.com

Xencor stock maintains Overweight rating at Cantor Fitzgerald ahead of key webcast  Investing.com

Xencor stock maintains Overweight rating at Cantor Fitzgerald ahead of key webcast - Investing.com

Click here to get full coverage on Xencor Stock Earns Relative Strength Rating Upgrade - Investor's Business Daily

Xencor Stock Earns Relative Strength Rating Upgrade  Investor's Business Daily

Xencor Stock Earns Relative Strength Rating Upgrade - Investor's Business Daily

Click here to get full coverage on Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release - Seeking Alpha

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release  Seeking Alpha

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release - Seeking Alpha

Click here to get full coverage on Xencor (XNCR) Sees Analyst Downgrade and Price Target Cut by B o - GuruFocus

Xencor (XNCR) Sees Analyst Downgrade and Price Target Cut by B o  GuruFocus

Xencor (XNCR) Sees Analyst Downgrade and Price Target Cut by B o - GuruFocus

Click here to get full coverage on Xencor Sees RS Rating Rise To 73 - Investor's Business Daily

Xencor Sees RS Rating Rise To 73  Investor's Business Daily

Xencor Sees RS Rating Rise To 73 - Investor's Business Daily

Click here to get full coverage on Rhenman & Partners Asset Management AB Has $1.30 Million Stake in Xencor, Inc. $XNCR - MarketBeat

Rhenman & Partners Asset Management AB Has $1.30 Million Stake in Xencor, Inc. $XNCR  MarketBeat

Rhenman & Partners Asset Management AB Has $1.30 Million Stake in Xencor, Inc. $XNCR - MarketBeat

Click here to get full coverage on Xencor Reports Second Quarter 2025 Financial Results - Business Wire

Xencor Reports Second Quarter 2025 Financial Results  Business Wire

Xencor Reports Second Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Xencor’s Promising NSCLC Study: A Potential Game-Changer? - TipRanks

Xencor’s Promising NSCLC Study: A Potential Game-Changer?  TipRanks

Xencor’s Promising NSCLC Study: A Potential Game-Changer? - TipRanks

Click here to get full coverage on Xencor issued U.S. patent for Xtend Fc domain - TipRanks

Xencor issued U.S. patent for Xtend Fc domain  TipRanks

Xencor issued U.S. patent for Xtend Fc domain - TipRanks

Click here to get full coverage on Xencor Earns Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily

Xencor Earns Relative Strength Rating Upgrade; Hits Key Benchmark  Investor's Business Daily

Xencor Earns Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily

Click here to get full coverage on Xencor Reports Initial Results from Phase 1 Studies - TipRanks

Xencor Reports Initial Results from Phase 1 Studies  TipRanks

Xencor Reports Initial Results from Phase 1 Studies - TipRanks

Click here to get full coverage on Stocks Showing Improving Market Leadership: Xencor Earns 83 RS Rating - Investor's Business Daily

Stocks Showing Improving Market Leadership: Xencor Earns 83 RS Rating  Investor's Business Daily

Stocks Showing Improving Market Leadership: Xencor Earns 83 RS Rating - Investor's Business Daily

Click here to get full coverage on Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates - PR Newswire

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates  PR Newswire

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates - PR Newswire

Click here to get full coverage on Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Call Transcript - Yahoo Finance

Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Call Transcript  Yahoo Finance

Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Call Transcript - Yahoo Finance

Click here to get full coverage on Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) - Yahoo Finance

Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)  Yahoo Finance

Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) - Yahoo Finance

Click here to get full coverage on Why Shares of Zencor Rose This Week - The Motley Fool

Why Shares of Zencor Rose This Week  The Motley Fool

Why Shares of Zencor Rose This Week - The Motley Fool

Click here to get full coverage on Xencor Stock Gains 23% on Encouraging Pipeline Advancements - TradingView — Track All Markets

Xencor Stock Gains 23% on Encouraging Pipeline Advancements  TradingView — Track All Markets

Xencor Stock Gains 23% on Encouraging Pipeline Advancements - TradingView — Track All Markets

Click here to get full coverage on Xencor Regains CD20 x CD3 Bispecific T-Cell Engager - Business Wire

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager  Business Wire

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager - Business Wire

Click here to get full coverage on Xencor: Q3 Earnings Snapshot - qz.com

Xencor: Q3 Earnings Snapshot - qz.com

Click here to get full coverage on Xencor: Once-Great R&D Behemoth With Emerging New Pipeline (NASDAQ:XNCR) - Seeking Alpha

Xencor: Once-Great R&D Behemoth With Emerging New Pipeline (NASDAQ:XNCR)  Seeking Alpha

Xencor: Once-Great R&D Behemoth With Emerging New Pipeline (NASDAQ:XNCR) - Seeking Alpha

Click here to get full coverage on Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect? - Nasdaq

Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?  Nasdaq

Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect? - Nasdaq

Click here to get full coverage on Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies - PR Newswire

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies  PR Newswire

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies - PR Newswire

Click here to get full coverage on Xencor Reports Second Quarter 2023 Financial Results - PharmiWeb.com

Xencor Reports Second Quarter 2023 Financial Results  PharmiWeb.com

XNCR

Price Chart

Key Statistics

Technicals

About XNCR

Latest News

Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR - MarketBeat

Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga

Barclays Raises XNCR Price Target to $26; Reaffirms Overweight R - GuruFocus

Advanced Charts

Top Gainers

Top Losers